Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May 1;7(5):e2410421.
doi: 10.1001/jamanetworkopen.2024.10421.

Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial

Lorenzo Cohen et al. JAMA Netw Open. .

Abstract

Importance: Patients with head and neck cancer who undergo radiotherapy can develop chronic radiation-induced xerostomia. Prior acupuncture studies were single center and rated as having high risk of bias, making it difficult to know the benefits of acupuncture for treating radiation-induced xerostomia.

Objective: To compare true acupuncture (TA), sham acupuncture (SA), and standard oral hygiene (SOH) for treating radiation-induced xerostomia.

Design, setting, and participants: A randomized, blinded, 3-arm, placebo-controlled trial was conducted between July 29, 2013, and June 9, 2021. Data analysis was performed from March 9, 2022, through May 17, 2023. Patients reporting grade 2 or 3 radiation-induced xerostomia 12 months or more postradiotherapy for head and neck cancer were recruited from community-based cancer centers across the US that were part of the Wake Forest National Cancer Institute Community Oncology Research Program Research Base. Participants had received bilateral radiotherapy with no history of xerostomia.

Interventions: Participants received SOH and were randomized to TA, SA, or SOH only. Participants in the TA and SA cohorts were treated 2 times per week for 4 weeks. Those experiencing a minor response received another 4 weeks of treatment.

Main outcomes and measures: Patient-reported outcomes for xerostomia (Xerostomia Questionnaire, primary outcome) and quality of life (Functional Assessment of Cancer Therapy-General) were collected at baseline, 4 (primary time point), 8, 12, and 26 weeks. All analyses were intention to treat.

Results: A total of 258 patients (201 men [77.9%]; mean [SD] age, 65.0 [9.16] years), participated from 33 sites across 13 states. Overall, 86 patients were assigned to each study arm. Mean (SD) years from diagnosis was 4.21 (3.74) years, 67.1% (n = 173) had stage IV disease. At week 4, Xerostomia Questionnaire scores revealed significant between-group differences, with lower Xerostomia Questionnaire scores with TA vs SOH (TA: 50.6; SOH: 57.3; difference, -6.67; 95% CI, -11.08 to -2.27; P = .003), and differences between TA and SA (TA: 50.6; SA: 55.0; difference, -4.41; 95% CI, -8.62 to -0.19; P = .04) yet did not reach statistical significance after adjustment for multiple comparisons. There was no significant difference between SA and SOH. Group differences in Functional Assessment of Cancer Therapy-General scores revealed statistically significant group differences at week 4, with higher scores with TA vs SOH (TA: 101.6; SOH: 97.7; difference, 3.91; 95% CI, 1.43-6.38; P = .002) and at week 12, with higher scores with TA vs SA (TA: 102.1; SA: 98.4; difference, 3.64; 95% CI, 1.10-6.18; P = .005) and TA vs SOH (TA: 102.1; SOH: 97.4; difference, 4.61; 95% CI, 1.99-7.23; P = .001).

Conclusions and relevance: The findings of this trial suggest that TA was more effective in treating chronic radiation-induced xerostomia 1 or more years after the end of radiotherapy than SA or SOH.

Trial registration: ClinicalTrials.gov Identifier: NCT02589938.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Rosenthal reported serving, with financial compensation, on scientific advisory boards for Merck. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Patient Flowchart
ECOG indicates Eastern Cooperative Oncology Group; HN, head and neck.
Figure 2.
Figure 2.. Least Squares Mean Model Estimates for Xerostomia Questionnaire Scores and Functional Assessment of Cancer Therapy–General (FACT-G) Scores by Treatment Group
A, Least squares mean model estimates for Xerostomia Questionnaire. Unadjusted baseline mean and 95% CIs presented for reference, but adjusted mean and 95% CIs are presented for weeks 4, 8, 12, and 26. There were statistically significant differences between true acupuncture and standard oral hygiene (P = .003) at week 4 and between sham acupuncture and standard oral hygiene at week 26, true acupuncture vs standard oral hygiene at week 8 (P = .02), week 12 (P = .03), and week 26 (P = .06). B, Least squares mean model estimates for FACT-G scores. Unadjusted baseline mean and 95% CIs presented for reference, but adjusted mean and 95% CIs are presented for weeks 4, 8, 12, and 26. There were statistically significant differences between true acupuncture vs standard oral hygiene at week 4 (P = .002) and between true acupuncture vs standard oral hygiene (P = .001) and true acupuncture vs sham acupuncture (P = .005) at week 12.
Figure 3.
Figure 3.. Response Rates Based on Xerostomia Questionnaire (XQ) Scores by Treatment Group at Each Time Point
Difference in distributions between true acupuncture (TA) and standard oral hygiene (SOH) was statistically significant at weeks 4, 8, and 12 (P = .03 for each time point). Difference in distribution between sham acupuncture (SA) and SOH was significant at week 12 (P = .01). Differences were assessed using χ2 tests. No response indicates any increase in XQ scores or decrease of less than 10 points; minor response, 10- to 19-point decrease in XQ score; and partial response, 20 points or more decrease in XQ score.

References

    1. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(3):695-704. doi:10.1016/S0360-3016(01)01512-7 - DOI - PubMed
    1. Pacholke HD, Amdur RJ, Morris CG, et al. . Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol. 2005;28(4):351-358. doi:10.1097/01.coc.0000158826.88179.75 - DOI - PubMed
    1. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):577-587. doi:10.1016/S0360-3016(99)00247-3 - DOI - PubMed
    1. Bertram U. Xerostomia: clinical aspects, pathology and pathogenesis. Acta Odontol Scand. 1967;25(suppl 49):e2410421. - PubMed
    1. Dreizen S, Brown LR, Handler S, Levy BM. Radiation-induced xerostomia in cancer patients: effect on salivary and serum electrolytes. Cancer. 1976;38(1):273-278. doi:10.1002/1097-0142(197607)38:1<273::AID-CNCR2820380141>3.0.CO;2-8 - DOI - PubMed

Publication types

Associated data